BioNTech SE ADR (NASDAQ: BNTX) kicked off on Friday, down -3.71% from the previous trading day, before settling in for the closing price of $103.56. Over the past 52 weeks, BNTX has traded in a range of $76.53-$131.49.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 843.27% over the last five years. While this was happening, its average annual earnings per share was recorded -182.93%. With a float of $239.44 million, this company’s outstanding shares have now reached $239.74 million.
The firm has a total of 3082 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.31%, operating margin of -30.81%, and the pretax margin is -10.38%.
BioNTech SE ADR (BNTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BioNTech SE ADR is 0.26%, while institutional ownership is 19.50%. The most recent insider transaction that took place on Nov 15 ’24, was worth 15,534,000. Before that another transaction happened on Nov 12 ’24, when Company’s Officer proposed sale 556,000 for $108.73, making the entire transaction worth $60,453,880.
BioNTech SE ADR (BNTX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 1.9 earnings per share (EPS), lower than consensus estimate (set at 2.45) by -0.55. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -182.93% per share during the next fiscal year.
BioNTech SE ADR (NASDAQ: BNTX) Trading Performance Indicators
Take a look at BioNTech SE ADR’s (BNTX) current performance indicators. Last quarter, stock had a quick ratio of 7.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.24. Likewise, its price to free cash flow for the trailing twelve months is 16.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit 0.67 in the next quarter and is forecasted to reach -3.67 in one year’s time.
Technical Analysis of BioNTech SE ADR (BNTX)
Analysing the last 5-days average volume posted by the [BioNTech SE ADR, BNTX], we can find that recorded value of 1.68 million was better than the volume posted last year of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 35.11%. Additionally, its Average True Range was 5.34.
During the past 100 days, BioNTech SE ADR’s (BNTX) raw stochastic average was set at 42.19%, which indicates a significant increase from 25.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.63% in the past 14 days, which was lower than the 47.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $113.54, while its 200-day Moving Average is $95.55. Now, the first resistance to watch is $102.81. This is followed by the second major resistance level at $105.90. The third major resistance level sits at $110.15. If the price goes on to break the first support level at $95.47, it is likely to go to the next support level at $91.22. Should the price break the second support level, the third support level stands at $88.13.
BioNTech SE ADR (NASDAQ: BNTX) Key Stats
The company with the Market Capitalisation of 23.91 billion has total of 239,740K Shares Outstanding. Its annual sales at the moment are 4,133 M in contrast with the sum of 1,007 M annual income. Company’s last quarter sales were recorded 1,369 M and last quarter income was 217,830 K.
